With the "Blink One" diagnostic platform, Jena-based company Blink Dx has introduced its new system for microfluidic-free digital PCR (dPCR) in the USA. This new point-of-care solution enables high-precision PCR analysis of samples in real time and thus ties in directly with the "Blink X" developer platform already available to cooperation partners.
As a cartridge system, the "Blink One" offers for the first time a modular solution for various ready-to-use nanoreactor bead assays, which can also be developed for the platform by other manufacturers. As the dPCR runs within small nanoreactor beads, simultaneous analysis of multiple biomarkers (multiplexing) is possible, improving the efficiency and accuracy of the analysis.
Blink is an agile partner in the InfectoGnostics research campus and has developed the new diagnostic platform in close collaboration with other InfectoGnostics partners. The "Blink X" as well as the "Blink One" are also used in the ongoing campus project ADA. Jens Hellwage, PhD, Managing Director of the InfectoGnostics research campus, accompanied the campus partner at the leading American trade fair for clinical products: "We are pleased that with the 'Blink One' now an open diagnostic platform for on-site use can be presented. This platform marks an important step in medical diagnostics and can significantly improve the way we analyze samples and diagnose infectious diseases. The development of new tests on this platform incorporates the expertise of various Thuringian companies and research institutions from the InfectoGnostics research campus."
For more information about the "Blink One" diagnostic platform, visit the official Blink AG website: www.blink-dx.com.